Epstein-Barr virus (EBV) is a member of the herpesvirus family and one of the most common human viruses on the planet. Most adults carry it: in many parts of Asia and the developing world, over 90 percent of children are infected before age ten, while in Western countries roughly half of children in that age group have been infected, with most of the rest catching it during adolescence or early adulthood. EBV was the first human virus identified as capable of causing cancer, yet for the vast majority of people who carry it, the virus produces no symptoms at all after the initial infection clears. That gap between how widespread EBV is and how serious its consequences can sometimes be makes it one of the more underappreciated infections in medicine.
How EBV Gets Into Your Body
EBV spreads mainly through saliva, which is why primary infection in teenagers and young adults is often called “the kissing disease.” Sharing drinks, utensils, or toothbrushes can also transmit it. Once the virus reaches you, it targets two main types of cells: the epithelial cells lining your throat and your B cells, a class of white blood cell central to the immune system. The virus uses different sets of surface proteins to break into each cell type. One protein complex that includes a molecule called gp42 latches onto a receptor found on B cells, while a separate complex without gp42 handles entry into epithelial cells.1PubMed Central. Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells This dual-entry strategy is part of what makes EBV so successful: it can replicate in the throat lining to produce new virus particles for transmission, and it can quietly set up permanent residence inside immune cells.
Symptoms of the First Infection
What you feel when you first encounter EBV depends heavily on your age. Children under about five who catch the virus almost never develop noticeable symptoms. The classic illness, infectious mononucleosis (“mono”), shows up mainly in teenagers and young adults, with the rate of symptomatic illness climbing steeply through the teenage years and peaking especially among girls.2PLOS ONE. Primary Epstein-Barr virus infection with and without infectious mononucleosis The hallmark symptoms of mono are a severe sore throat, swollen lymph nodes in the neck, persistent fatigue, and fever that can last several weeks.3PubMed Central. Infectious Mononucleosis
Beyond those four cardinal symptoms, mono can also cause an enlarged spleen, which is why doctors tell patients to avoid contact sports during recovery. Some people develop a faint rash, and a notable minority feel lingering fatigue for months after the sore throat and fever have resolved. About one in ten patients still reports significant fatigue six months later.4PubMed Central. Antiviral agents for infectious mononucleosis (glandular fever) For most people, though, mono eventually resolves on its own without lasting damage.
Why the Virus Never Truly Leaves
EBV is a herpesvirus, and like all herpesviruses, it establishes a lifelong latent infection. After the initial bout of illness (or the silent infection in childhood), the virus retreats into a specific compartment of your immune system: memory B cells. These are long-lived immune cells that your body maintains for decades as part of its normal defenses. EBV essentially hijacks the same biological machinery that keeps those cells alive indefinitely.5PubMed. EBV persistence in memory B cells in vivo During latency, the virus silences most of its own genes, producing very few viral proteins. This keeps it nearly invisible to the immune system.6PubMed Central. Epstein-Barr virus: a master epigenetic manipulator
Periodically, EBV can reactivate from this dormant state, switching back to active replication. You usually shed some virus in your saliva during these episodes, even if you feel perfectly fine. Reactivation is more likely when the immune system is weakened by stress, other infections, or immunosuppressive drugs.7PubMed Central. Stress-Induced Epstein-Barr Virus Reactivation Research has found that infections with other pathogens, including HIV, hepatitis viruses, herpes simplex virus, and even SARS-CoV-2, can trigger EBV to wake up.8PubMed Central. Awakening the sleeping giant: Epstein-Barr virus reactivation by biological agents More recent work suggests that certain genetic variants in genes governing the inflammatory protein interleukin-1 make some people more susceptible to reactivation than others, pointing toward a genetic component to who reactivates frequently and who does not.9PubMed. The SARS-CoV-2 trigger highlights host interleukin 1 genetics in Epstein-Barr virus reactivation
The Link to Multiple Sclerosis
The most striking long-term consequence associated with EBV is its connection to multiple sclerosis (MS). A landmark 2022 study tracking millions of military personnel found that EBV infection dramatically increased the risk of later developing MS, leading the authors to conclude that EBV infection is a trigger for the disease.10PubMed. Epstein-Barr virus and multiple sclerosis Epidemiological data broadly support this, with EBV now described as a requisite risk factor for MS, meaning that virtually all MS patients show evidence of prior EBV infection. Still, how EBV actually causes MS remains unclear.11PubMed Central. Epstein-Barr Virus in Multiple Sclerosis: Past, Present, and Future
A key reason this is so perplexing is scale: more than 90 percent of adults carry EBV, yet fewer than one in a thousand develop MS. Something else has to be present beyond the virus itself. Researchers are investigating whether certain immune-system genes, vitamin D levels, smoking, and the timing of infection all interact with EBV exposure to produce the disease in susceptible individuals. A small open-label trial explored treating progressive MS with immune cells specifically trained to attack EBV-infected cells. Six of ten patients showed both symptomatic and objective neurological improvement, particularly those who received T cells with strong reactivity against the virus.12PubMed Central. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis It is early-stage work, but it supports the idea that targeting EBV directly could be a future MS treatment strategy.
Other Autoimmune Connections
MS is not the only autoimmune condition linked to EBV. The virus has been associated with rheumatoid arthritis (RA), where its ability to persist in B cells and modulate the immune system may contribute to the chronic inflammation characteristic of the disease.13PubMed Central. Epstein-Barr virus and rheumatoid arthritis: is there a link? Systemic lupus erythematosus (SLE) is another condition with a notable EBV connection. Lupus patients carry a dramatically higher burden of the virus in their blood, with studies showing a five-to-40-fold increase in EBV DNA levels compared to healthy people, driven by a larger pool of latently infected memory B cells.14PubMed Central. Epstein-Barr Virus in Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis—Association and Causation
Whether EBV causes these autoimmune diseases or is simply more active in people whose immune systems are already dysregulated is an ongoing debate. The relationship may be bidirectional: the virus provokes immune abnormalities, and those abnormalities in turn allow the virus to replicate more freely. Either way, these connections have made EBV a growing focus in autoimmune disease research.
EBV and Cancer
EBV was the first virus shown to cause cancer in humans, and its association with several malignancies is now well established. The cancers most strongly linked to EBV include nasopharyngeal carcinoma, Burkitt lymphoma, Hodgkin lymphoma, and certain gastric cancers.15PubMed Central. Epstein-Barr virus BART microRNAs in EBV-associated Hodgkin lymphoma and gastric cancer
Nasopharyngeal carcinoma is common in specific regions, particularly southern China and Southeast Asia, and its incidence clusters in certain ethnic groups. While EBV infection is ubiquitous worldwide, the cancer clearly requires additional environmental and genetic factors to develop.16PubMed Central. The role of Epstein-Barr virus in nasopharyngeal carcinoma Burkitt lymphoma, meanwhile, occurs most frequently in equatorial Africa where malaria is endemic. The prevailing theory is that repeated malaria infections drive the expansion and reactivation of EBV-infected B cells, dramatically raising the chance of the genetic rearrangement that gives rise to the tumor.17PubMed Central. The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma
The common thread across these cancers is that EBV alone is rarely sufficient. The virus interacts with co-infections, genetics, diet, and other environmental exposures over years or decades before a malignancy develops. For the average healthy carrier of EBV, the absolute risk of any of these cancers is very low.
Chronic Fatigue Syndrome and Long COVID
A growing body of research connects EBV reactivation to post-viral fatigue syndromes, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID. Both conditions share a remarkably similar symptom profile: crushing fatigue, exercise intolerance, sleep disturbance, cognitive difficulties, and gastrointestinal problems. Both also show elevated markers of EBV reactivation. One proposal is that latent EBV, awakened either by the initial illness or by the immune disruption it causes, drives an ongoing cycle of immune dysfunction and chronic inflammation.18PubMed Central. Epstein-Barr virus-acquired immunodeficiency in myalgic encephalomyelitis-Is it present in long COVID?
Laboratory studies have found that patients with both ME/CFS and long COVID show heightened antibody responses against EBV proteins, suggesting more frequent or more vigorous viral reactivation in these groups.19PubMed Central. Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID This does not prove EBV reactivation is the cause of these syndromes, but it has intensified interest in whether antiviral or immune-modulating therapies targeting EBV could help patients with post-viral illness.
How EBV Is Diagnosed
Doctors diagnose acute EBV infection using a combination of symptoms and blood tests. A quick “monospot” test detects heterophile antibodies, which are antibodies the body produces in response to mono (but not specifically to EBV). The monospot is convenient but can miss infections, especially in young children. More specific blood tests measure antibodies directly against EBV proteins. A standard panel looks at three markers: antibodies against the viral capsid antigen (VCA IgG and VCA IgM) and antibodies against a nuclear antigen called EBNA-1. The typical pattern for a new infection is positive VCA IgM and VCA IgG without EBNA-1 IgG, while someone with a past infection will have VCA IgG and EBNA-1 IgG but no VCA IgM.20PubMed Central. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions
This sounds clean in theory, but the real-world picture is muddier. In one study of patients suspected of having primary EBV infection who tested positive for all three antibody types, fewer than half actually had a new infection. Nearly a quarter were experiencing EBV reactivation, not a first-time infection, and the VCA IgM positivity was misleading. The presence or absence of heterophile antibodies turned out to be a surprisingly useful tiebreaker: almost all primary infections tested positive for heterophile antibodies, while reactivation cases almost never did.21PubMed. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis When the antibody picture is ambiguous, additional tests such as IgG avidity testing or direct measurement of viral DNA in the blood can help sort things out.
Treatment and Why Antivirals Do Not Help Much
There is no cure for EBV, and the virus persists for life. For typical mono, treatment is supportive: rest, fluids, and over-the-counter pain relievers for the sore throat and fever. Antiviral drugs like acyclovir can temporarily suppress EBV replication in the throat, but virus shedding bounces back within a week of stopping the drug, and the clinical course of the illness does not meaningfully change.22PubMed. Acyclovir treatment in infectious mononucleosis: a clinical and virological study A Cochrane systematic review concluded that while antiviral-treated patients may recover slightly sooner by physician assessment, the difference is small enough to be of limited clinical significance.4PubMed Central. Antiviral agents for infectious mononucleosis (glandular fever)
The reason standard antivirals fail against EBV makes sense once you understand how the virus persists. Drugs like acyclovir target the replication machinery the virus uses to make new copies of itself. But the vast reservoir of EBV lives in latently infected memory B cells, where the virus is not actively replicating. The drug can attack the small amount of active virus in the throat but cannot touch the silent pool that maintains lifelong infection.
For the rare and serious condition known as chronic active EBV (CAEBV), where the virus produces ongoing illness rather than settling into quiet latency, the treatment landscape is evolving. Newer immunotherapy approaches, including checkpoint inhibitors and EBV-specific T-cell therapy, have shown promise.23PubMed Central. Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease Stem-cell transplantation remains an option for severe cases. CAEBV-associated hemophagocytic lymphohistiocytosis (HLH), a life-threatening inflammatory condition, follows different patterns depending on whether it arises from an acute or chronic EBV infection. The acute form tends to be more explosively inflammatory, while the chronic form more often involves the central nervous system and runs a longer, though still serious, course.24PubMed Central. Distinct Clinical and Prognostic Features of Acute and Chronic Active Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Adults: A Scoping Review
The Search for a Vaccine
Given that EBV is tied to multiple sclerosis, several cancers, and potentially chronic fatigue syndromes, the case for a vaccine is compelling. Yet no approved EBV vaccine exists. The virus’s complexity, its dual-cell-type infection strategy, and its ability to hide in latency have all made vaccine development difficult. Researchers are now applying mRNA vaccine technology, accelerated by the COVID-19 pandemic, to EBV. Computational approaches have identified vaccine constructs with strong predicted immunogenicity and broad population coverage, and several candidates are moving toward clinical testing.25PubMed Central. mRNA vaccine design for Epstein-Barr virus: an immunoinformatic approach Whether a vaccine would need to prevent infection entirely or simply reduce the viral load enough to prevent downstream diseases remains an open question that will shape how clinical trials are designed.
An Ancient Virus With Primate Roots
EBV is not unique to humans. Closely related viruses, collectively called lymphocryptoviruses, infect primates across the evolutionary tree. The phylogeny of these viruses largely mirrors the branching of primate species, suggesting that EBV-like viruses have been co-evolving with primate hosts for tens of millions of years, since the split between Old World and New World primates.26PubMed. Lymphocryptovirus phylogeny and the origins of Epstein-Barr virus Mountain gorillas carry their own version of the virus, with amino acid sequences roughly 91 to 97 percent similar to human EBV depending on the gene examined, and the infection follows a strikingly similar pattern in gorilla infants as it does in human children.27Scientific Reports. Mountain gorilla lymphocryptovirus has Epstein-Barr virus-like epidemiology and pathology in infants
This deep evolutionary history helps explain why EBV is so extraordinarily well-adapted to human biology. The virus has had millions of years of coevolution to refine its strategy of infecting B cells, evading the immune system, and persisting for a lifetime. It also means the relationship between host and virus is not entirely hostile. Most carriers live their entire lives without EBV causing them any trouble at all. The diseases linked to EBV, from mono to MS to cancer, may represent the collateral damage of a generally stable coexistence that occasionally goes wrong, especially when other genetic or environmental factors tip the balance.